Condition: Advanced Soft Tissue Sarcoma · Metastatic Soft Tissue Sarcoma · Sponsor: Sarcoma Oncology Research Center, LLC
This is an open label, dose-seeking phase 1/2 study using escalating doses of TRABECTEDIN given intravenously with defined doses of IPILIMUMAB and NIVOLUMAB based on preliminary results of the Checkmate 012 trial for NSCLC (Hellman et al., 2016). For the Phase 1 Part of Study, only previously treated patients will be enrolled. For the Phase 2 Part of Study, previously treated patients will be enrolled.
This description comes directly from the study's public registry record.
Erlinda M Gordon, MD · 310-552-9999 · egordon@sarcomaoncology.com
Victoria Chua-Alcala, MD · 310-552-9999 · vchua@sarcomaoncology.com
Always discuss trial participation with your own doctor first.
| Sarcoma Oncology Research Center | Santa Monica, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03138161